Abstract:Background ALK rearrangement-advanced NSCLC patients respond to crizotinib. ALK rearrangement is currently determined with RT-PCR. VENTANA IHC is a standard method to identify ALK protein overexpression in NSCLC; however, VENTANA IHC has rarely been used to determine the response to crizotinib in Chinese patients with NSCLC and ALK overexpression. To better clarify the clinical implication of VENTANA IHC to detect ALK rearrangements, we conducted this study to analyze VENTANA IHC and RT-PCR in a large cohort of Chinese patients with NSCLC undergoing screening for ALK rearrangements. Methods A total of 1720 patients with NSCLC who had ALK rearrangements detected by VENTANA IHC and/or RT-PCR were included in this analysis. We compared the efficacy and survival of ALK-positive patients detected by VENTANA IHC and RT-PCR. We used NGS to identify patients in whom the two methods were inconsistent. Results Among 1720 patients, 187 (10.87%) were shown to be ALK-positive by VENTANA IHC and/or RT-PCR, and 66 received crizotinib treatment. We identified 10.27% (172/1674) of patients as ALK-positive by the VENTANA IHC method, and 12.73% (41/322) of patients had ALK rearrangements by the RT-PCR method. Twenty-nine of 276 (10.51%) ALK-positive patients were simultaneously analyzed using VENTANA IHC and RT-PCR. The overall response rates were 65.90% (29/44) by VENTANA IHC and 55.88% (19/34) by RT-PCR. The disease control rates were 86.36% (38/44) by VENTANA IHC and 76.47% (26/34) by RT-PCR. In contrast, the median progression-free survival for VENTANA IHC and RT-PCR was 8.5 and 9.2 months, respectively. The VENTANA IHC and RT-PCR results obtained for 6 of 17 ALK-positive patients were inconsistent based on NGS; specifically, 4 patients had EML4 - ALK fusions, 2 patients had non EML4 - ALK fusions, 1 patient had a KCL1 - ALK fusion, and one patient had a FBXO36 - ALK fusion. Conclusions VENTANA IHC is a reliable and rapid screening tool used in routine pathologic laboratories for the identification of suitable candidates for ALK -targeted therapy. VENTANA IHC has moderate sensitivity and a slightly higher association with response to therapy with ALK inhibitors, and some VENTANA IHC-positive, but RT-PCR-negative cases may benefit from crizotinib.

Detection of EML4-ALK gene rearrangement in NSCLC by Ventana IHC and the challenges for diagnosis

[ALK gene fusion associated non-small cell lung cancer: automated immunostainer detection and clinicopathologic perspectives]

Concordance of Immunohistochemistry and Fluorescent in Situ Hybridization for Anaplastic Lymphoma Kinase (alk) Rearrangement in Non-Small Cell Lung Cancer: Results from A Multicenter Study in China

Accurate and Economical Detection of ALK Positive Lung Adenocarcinoma with Semiquantitative Immunohistochemical Screening

Evaluation Of Alk Rearrangement In Chinese Non-Small Cell Lung Cancer Using Fish, Immunohistochemistry, And Real-Time Quantitative Rt- Pcr On Paraffin-Embedded Tissues

Detection of ALK protein in lung squamous cell carcinoma with immunohistochemistry and FISH

Comparative study of ALK antibody with manual and automatic immunohistochemical detec-tion in non-small cell lung cancer

Non-small cell lung cancer with EML4-ALK positive expression: a clinicopathological analysis of 72 cases

Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib

Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry

Comparing Four Different ALK Antibodies with Manual Immunohistochemistry (IHC) to Screen for ALK-rearranged Non-Small Cell Lung Cancer (NSCLC).

Parallel Ventana Ihc And R.-Pcp Of Ack Status In Non-Small Cell Lung Cancer And Response To Crizotinib.

Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring Alk Rearrangements Detected by Fish, Ihc, and Rt-Pcr

Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.

Exploration of ALK fused gene expression in non-small cell lung cancer patients by immuno-histochemistry

Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis.

Alk-Rearranged Lung Cancer In Chinese: A Comprehensive Assessment Of Clinicopathology, Ihc, Fish And Rt-Pcr

Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC

Detection of EML4-ALK in Lung Adenocarcinoma Using Pleural Effusion with FISH, IHC, and RT-PCR Methods

Eml4-Alk Rearrangement And Its Clinical Significance In Chinese Patients With Advanced Non-Small Cell Lung Cancer

The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy.